|
1
|
Cleator S, Heller W and Coombes RC:
Triple-negative breast cancer: Therapeutic options. Lancet Oncol.
8:235–244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao
CK, Chang KJ and Chuang EY: Molecular characteristics and
metastasis predictor genes of triple-negative breast cancer: A
clinical study of triple-negative breast carcinomas. PLoS One.
7:e458312012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen JQ and Russo J: ERalpha-negative and
triple negative breast cancer: Molecular features and potential
therapeutic approaches. Biochim Biophys Acta. 1796:162–175.
2009.PubMed/NCBI
|
|
4
|
Garcia R, Bowman TL, Niu G, Yu H, Minton
S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, et
al: Constitutive activation of Stat3 by the Src and JAK tyrosine
kinases participates in growth regulation of human breast carcinoma
cells. Oncogene. 20:2499–2513. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garcia R, Yu CL, Hudnall A, Catlett R,
Nelson KL, Smithgall T, Fujita DJ, Ethier SP and Jove R:
Constitutive activation of Stat3 in fibroblasts transformed by
diverse oncoproteins and in breast carcinoma cells. Cell Growth
Differ. 8:1267–1276. 1997.PubMed/NCBI
|
|
6
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
|
7
|
Imada K and Leonard WJ: The Jak-STAT
pathway. Mol Immunol. 37:1–11. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Darnell JE Jr: STATs and gene regulation.
Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thomas SJ, Snowden JA, Zeidler MP and
Danson SJ: The role of JAK/STAT signalling in the pathogenesis,
prognosis and treatment of solid tumours. Br J Cancer. 113:365–371.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rundhaug JE: Matrix metalloproteinases,
angiogenesis, and cancer: commentary re: A. C. Lockhart et al.,
Reduction of wound angiogenesis in patients treated with
BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.
Clin. Cancer Res. 9:00-00, 2003. Clin Cancer Res 9. 551–554.
2003.
|
|
12
|
Verma RP and Hansch C: Matrix
metalloproteinases (MMPs): Chemical-biological functions and
(Q)SARs. Bioorg Med Chem. 15:2223–2268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Visse R and Nagase H: Matrix
metalloproteinases and tissue inhibitors of metalloproteinases:
Structure, function, and biochemistry. Circ Res. 92:827–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brooks PC, Strömblad S, Sanders LC, von
Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP and
Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the
surface of invasive cells by interaction with integrin αvβ3. Cell.
85:683–693. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rojiani MV, Alidina J, Esposito N and
Rojiani AM: Expression of MMP-2 correlates with increased
angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp
Pathol. 3:775–781. 2010.PubMed/NCBI
|
|
16
|
Zheng H, Takahashi H, Murai Y, Cui Z,
Nomoto K, Niwa H, Tsuneyama K and Takano Y: Expressions of MMP-2,
MMP-9 and VEGF are closely linked to growth, invasion, metastasis
and angiogenesis of gastric carcinoma. Anticancer Res.
26A:3579–3583. 2006.
|
|
17
|
Xie TX, Huang FJ, Aldape KD, Kang SH, Liu
M, Gershenwald JE, Xie K, Sawaya R and Huang S: Activation of stat3
in human melanoma promotes brain metastasis. Cancer Res.
66:3188–3196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F,
Sawaya R and Huang S: Stat3 activation regulates the expression of
matrix metalloproteinase-2 and tumor invasion and metastasis.
Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee JW, Kwak HJ, Lee JJ, Kim YN, Lee JW,
Park MJ, Jung SE, Hong SI, Lee JH and Lee JS: HSP27 regulates cell
adhesion and invasion via modulation of focal adhesion kinase and
MMP-2 expression. Eur J Cell Biol. 87:377–387. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Valenzuela A and Garrido A: Biochemical
bases of the pharmacological action of the flavonoid silymarin and
of its structural isomer silibinin. Biol Res. 27:105–112.
1994.PubMed/NCBI
|
|
21
|
Singh RP and Agarwal R: Cosmeceuticals and
silibinin. Clin Dermatol. 27:479–484. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Loguercio C and Festi D: Silybin and the
liver: From basic research to clinical practice. World J
Gastroenterol. 17:2288–2301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kosina P, Kren V, Gebhardt R, Grambal F,
Ulrichová J and Walterová D: Antioxidant properties of silybin
glycosides. Phytother Res. 16 Suppl 1:S33–S39. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dehmlow C, Murawski N and de Groot H:
Scavenging of reactive oxygen species and inhibition of arachidonic
acid metabolism by silibinin in human cells. Life Sci.
58:1591–1600. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tyagi AK, Singh RP, Agarwal C, Chan DC and
Agarwal R: Silibinin strongly synergizes human prostate carcinoma
DU145 cells to doxorubicin-induced growth Inhibition,
G2-M arrest, and apoptosis. Clin Cancer Res.
8:3512–3519. 2002.PubMed/NCBI
|
|
26
|
Agarwal C, Singh RP, Dhanalakshmi S, Tyagi
AK, Tecklenburg M, Sclafani RA and Agarwal R: Silibinin upregulates
the expression of cyclin-dependent kinase inhibitors and causes
cell cycle arrest and apoptosis in human colon carcinoma HT-29
cells. Oncogene. 22:8271–8282. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bosch-Barrera J and Menendez JA: Silibinin
and STAT3: A natural way of targeting transcription factors for
cancer therapy. Cancer Treat Rev. 41:540–546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tyagi A, Agarwal C, Dwyer-Nield LD, Singh
RP, Malkinson AM and Agarwal R: Silibinin modulates TNF-α and IFN-γ
mediated signaling to regulate COX2 and iNOS expression in
tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog.
51:832–842. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lim EJ, Hong DY, Park JH, Joung YH, Darvin
P, Kim SY, Na YM, Hwang TS, Ye SK, Moon ES, et al:
Methylsulfonylmethane suppresses breast cancer growth by
down-regulating STAT3 and STAT5b pathways. PLoS One. 7:e333612012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Björklund M and Koivunen E:
Gelatinase-mediated migration and invasion of cancer cells. Biochim
Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
|
|
31
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: A population-based study from the California cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dent R, Hanna WM, Trudeau M, Rawlinson E,
Sun P and Narod SA: Pattern of metastatic spread in triple-negative
breast cancer. Breast Cancer Res Treat. 115:423–428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gluz O, Liedtke C, Gottschalk N, Pusztai
L, Nitz U and Harbeck N: Triple-negative breast cancer - current
status and future directions. Ann Oncol. 20:1913–1927. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chu SC, Chiou HL, Chen PN, Yang SF and
Hsieh YS: Silibinin inhibits the invasion of human lung cancer
cells via decreased productions of urokinase-plasminogen activator
and matrix metalloproteinase-2. Mol Carcinog. 40:143–149. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nambiar D, Prajapati V, Agarwal R and
Singh RP: In vitro and in vivo anticancer efficacy of silibinin
against human pancreatic cancer BxPC-3 and PANC-1 cells. Cancer
Lett. 334:109–117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Singh RP, Deep G, Blouin MJ, Pollak MN and
Agarwal R: Silibinin suppresses in vivo growth of human prostate
carcinoma PC-3 tumor xenograft. Carcinogenesis. 28:2567–2574. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Darvin P, Joung YH, Sp N, Kang DY, Byun
HJ, Hwang DY, Cho KH, Park KD, Lee HK and Yang YM: Sorghum
polyphenol suppresses the growth as well as metastasis of colon
cancer xenografts through co-targeting jak2/STAT3 and PI3K/Akt/mTOR
pathways. J Funct Foods. 15:193–206. 2015. View Article : Google Scholar
|
|
39
|
Darvin P, Baeg SJ, Joung YH, Sp N, Kang
DY, Byun HJ, Park JU and Yang YM: Tannic acid inhibits the
Jak2/STAT3 pathway and induces G1/S arrest and mitochondrial
apoptosis in YD-38 gingival cancer cells. Int J Oncol.
47:1111–1120. 2015.PubMed/NCBI
|
|
40
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bauvois B: New facets of matrix
metalloproteinases MMP-2 and MMP-9 as cell surface transducers:
Outside-in signaling and relationship to tumor progression. Biochim
Biophys Acta. 1825:29–36. 2012.PubMed/NCBI
|
|
42
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
